Pharmaceutical Non-Active Ingredients TRIZ Cases

A polymeric backbone replaces complex ADC linkers to improve selective tumor delivery, therapeutic index, and manufacturing simplicity.

Using Bsmoc-protected lysine and carbodiimide coupling, this case improves peptide yield and purity by limiting byproducts and purification.

Multiple carbohydrate transport pathways and balanced electrolytes raise intake to 120-160 g/h while reducing gastrointestinal distress.

Targeted bardoxolone methyl use improves kidney function in Alport syndrome while excluding patients at higher endothelial dysfunction risk.

A gellan gum-starch shell composition improves soft capsule forming, resists gastric acid, and avoids leakage without enteric coating.

Glycan-linked Trop-2 antibody conjugates control payload ratio and uniformity to improve safety, stability, and antitumor activity.

Active targeting moieties on PEG drug conjugates improve tumor delivery while reducing systemic toxicity and formulation complexity.

A CD25-binding aptamer blocks IL-2 signaling and selectively depletes tumor Tregs while limiting autoimmune side effects.

pH-responsive liposomes use apolipoprotein targeting and acidic tumor release to improve andrographolide delivery in lymphoma.

Cyclic acetal protection enables high-purity PEG aldehyde derivatives with stable chain integrity, efficient conversion, and no column chromatography.

Limiting water to 20% and nitrite/nitrate to 2 ppm helps amine-containing pharmaceutical compositions stay storage-stable and within nitrosamine limits.

Hydrolysable linkers enable consistent release of amine- and hydroxyl-bearing drugs under physiological conditions without enzyme variability.

ARRDC1-mediated microvesicles deliver proteins and nucleic acids to retinal tissue while avoiding viral vector immune response and cargo limits.

Heating protected maleimide PEG with silica gel enables deprotection while limiting maleimide deterioration and maintaining high maleimidization.

Reversible drug linkers and degradable crosslinks let hyaluronic acid hydrogels balance drug loading with hyaluronidase-driven release.

A water-polysaccharide gel stores latent heat while staying shape stable, preventing liquid flow and volume change in thermal storage.

ASGPR-binding carbohydrate conjugates improve oligonucleotide uptake and nuclease stability, supporting stronger gene silencing in therapy.

Polyvalent cations coat liver and kidney vascular surfaces to slow drug clearance, extend blood retention, and improve delivery to target organs.

Small-molecule PSMA conjugates use cleavable linkers to localize cytotoxic payloads at prostate tumors while improving uptake and lowering toxicity.

Boosting MHC expression with rimantadine or PEGylated adamantane derivatives can improve antigen presentation and anti-PD-1 response.

Continuous transdermal theophylline delivery replaces daily injections and maintains steady plasma levels for chronic demyelination treatment.

Cholic acid and a polyvinyl polymer stabilize poorly soluble RK-33 as an aqueous IV suspension, limiting aggregation and precipitation.

A dual linker adds two drugs to one antibody while hydrophilic and cleavable elements improve ADC solubility and delivery to cancer cells.

A thermoresponsive polymer-drug gel forms a local joint reservoir for sustained anti-inflammatory release while reducing repeat injections and systemic exposure.

A biweekly liposomal irinotecan, oxaliplatin, 5-fluorouracil, and leucovorin regimen improves tolerability while preserving anti-tumor activity.

A dual-release HDAC inhibitor reaches target plasma levels quickly and maintains them for at least 48 hours to support cancer pretreatment.

A four-layer PEI, alginate, chitosan, and wild strawberry polysaccharide film improves moisture resistance and structural stability for controlled release.

Polyvalent cations adsorb on liver and kidney endothelium to suppress drug clearance and extend bloodstream retention.

Engineered extracellular vesicles use dual cleavable linkers to carry higher therapeutic payloads with targeted release and lower systemic exposure.

Two stimulus-reactive moieties keep a PROTAC inactive until both triggers are present, improving degradation selectivity and limiting off-target toxicity.

Polyunsaturated fatty acid salt lubricants improve tablet compression and ejection without the dissolution delays or health concerns of magnesium stearate.

A solvent-free conjugation and cross-linking route avoids polar organic residues while producing biocompatible hydrogel scaffolds for tissue regeneration.

Microfluidic mixing and in-process solvent removal enable scalable liposomal adjuvant production with consistent quality and retained immunological effect.

Specific nucleotide linkers improve serum protein binding, nuclease resistance, and intracellular trafficking for stronger RNA knockdown.

Anilino-linked glucocorticoid agonists improve stability and anti-inflammatory potency while reducing side effects in immunoconjugates.

Controlled drying and low-water solvent use keep activated PEG derivatives high in purity while limiting thermal history and polydispersity.

An oral mucosal film uses permeation enhancers and epinephrine prodrugs to reach rapid therapeutic levels comparable to intramuscular injection.

Hydrophilic linker structures let ADCs carry higher drug loads while preserving solubility, stability, and favorable pharmacokinetics.

A long-acting PEGylated SN-38 prodrug uses slow release and gapped PARP inhibitor dosing to sustain tumor DNA damage with lower myelosuppression.

A multi-extract herbal composition targets bacteria, fungi, and resistant strains without antibiotics, reducing toxicity and treatment gaps.

Small-molecule CA-IV binders mediate BBB transcytosis, enabling therapeutic cargo delivery to the CNS without invasive methods.

Star-shaped graft copolymers self-assemble into nanoscale carriers that improve payload delivery while reducing toxicity and immunogenicity.